China Pharma Holdings vs Merck & Company: Fair Value & Quality
Both stocks run through our valuation models. Here is how China Pharma Holdings (CPHI) and Merck & Company (MRK) compare, as of Aug 29, 2026.
As of Aug 29, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: China Pharma Holdings trades at $0.90 versus a fair value of $0.38 (-58%), while Merck & Company trades at $148 versus $125 (-16%).
China Pharma Holdings
CPHI · USD · Health Care
-58%
upside to fair value
overvalued
Price$0.90
Fair Value$0.38
Quality37/100
Merck & Company
MRK · USD · Health Care
-16%
upside to fair value
overvalued
Price$148
Fair Value$125
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
China Pharma HoldingsMerck & Company
Valuation
—P/E (TTM)42.9×
7.83×P/S (TTM)4.64×
1.37×P/B5.80×
—EV/EBITDA11.4×
0.16×PEG6.10×
—Dividend yield2.2%
—Dividend per share$3.28
Profitability
-89%Net margin14%
-114%Operating margin39%
-16%Return on equity19%
-7%Return on assets13%
Growth
-13%Revenue growth (YoY)5%
-20.0%Avg. growth/yr (3Y)3.1%
-17.5%Avg. growth/yr (5Y)9.4%
Balance & size
0.06×Debt / equity0.89×
$31MMarket cap$305B
weakGrowth qualityhealthy
Merck & Company leads: 3 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
China Pharma Holdingsof which business quality 38 · market factors 42Merck & Companyof which business quality 68 · market factors 87
ProfitabilityMargins and returns on capital today
0
74
Quality GrowthAre margins and returns improving?
60
36
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
31
71
Low VolatilityCalm price path (market factor)
31
83
MomentumPrice trend over the last 3–12 months (market factor)
65
82
52W MomentumDistance to the 52-week high (market factor)
13
100
Net IssuanceBuybacks instead of dilution
100
91
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
China Pharma Holdings
Asset-Based$0.38
1 of 1 models see the stock below the current price.
Merck & Company
DCF Models$117
Earnings-Based$62.77
Dividend Discount$60.35
Multiples$122
Asset-Based$14.27
Growth DCF$74.00
Economic Profit$83.85
Growth Earnings$138
23 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
China Pharma Holdings
Bear $0.28Fair Value $0.38Bull $0.56
$0.90 = current price (white tick)
Merck & Company
Bear $70.92Fair Value $125Bull $188
$148 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
China Pharma Holdings · Health Care
Quality score37 · bottom 25%
Fair value upside-58% · below median
Merck & Company · Health Care
Quality score70 · Top 25%
Fair value upside-16% · above median
Bottom line
As of Aug 29, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: China Pharma Holdings trades at $0.90 versus a fair value of $0.38 (-58%), while Merck & Company trades at $148 versus $125 (-16%).
Merck & Company has the higher quality score (70/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.
